Section Arrow
GILD.NASDAQ
- Gilead Sciences
Quotes are at least 15-min delayed:2026/03/09 20:36 EDT
Regular Hours
Last
 146.63
+2.7 (+1.88%)
Day High 
146.92 
Prev. Close
143.93 
1-M High
157.29 
Volume 
5.21M 
Bid
146.11
Ask
147.48
Day Low
143.485 
Open
143.5 
1-M Low
142.77 
Market Cap 
178.68B 
Currency 美元 
P/E 21.1 
%Yield 2.71 
10-SMA 147.25 
20-SMA 149.85 
50-SMA 137.75 
52-W High 157.29 
52-W Low 93.37 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
6.78/9.35
Enterprise Value
200.81B
Balance Sheet
Book Value Per Share
18.29
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
29.44B
Operating Revenue Per Share
22.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MDCXMedicus Pharma Ltd0.5099+0.1247+32.37%-- 
PFEPfizer26.81-0.24-0.89%19.84PE
NVONovo-Nordisk A/S39.78+1.2+3.11%10.75PE
BMYBristol-Myers Squibb Co60.63+0.34+0.56%17.41PE
MRKMerck & Co117.11+1.32+1.14%15.9PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.